eli lilly numbers up, page-4

New Acrux released... sounds good

ACRUX (ACR) - ASX ANNOUNCEMENT 31 JANUARY 2014
AXIRON NET SALES FOR CALENDAR YEAR 2013
Acrux (ASX: ACR) today confirmed that Eli Lilly reported Axiron net sales of
US$53.9 million in its financial results for the quarter ended 31 December 2013, up from
US$40.6 million for the previous quarter to 30 September 2013.
Global Axiron net sales for the 2013 calendar year are shown in the following table:
Q1 2013 Q2 2013 Q3 2013 Q4 2013 Total for 2013
US$37.1m US$47.1m US$40.6m US$53.9m US$178.7m
In addition to royalties on these net sales, Acrux will receive a milestone payment of
US$25 million in March 2014, as the worldwide net sales of Axiron in the 2013 calendar
year exceeded US$100 million. As advised previously, funds that are superfluous to
working capital requirements will be distributed to shareholders as dividends. We remain
confident about the net sales growth prospects for calendar 2014.
Contact